Bright Health Group Reports Fourth Quarter and Full Year 2021 Results


MINNEAPOLIS–(BUSINESS WIRE)–Bright Health Group, Inc. (“Bright Health” or the “Company”) (NYSE: BHG), a diversified healthcare services company building a technology-enabled, fully-aligned, national Integrated System of Care personalized for consumers, today reported financial results for its fourth quarter and full year ended December 31, 2021.

Bright Health Group achieved substantial growth in 2021, delivering $4 billion in Revenue, and reaching a significant scale milestone of serving over 1 million health plan lives for the start of 2022. While progressing on important foundational capabilities, this level of growth created challenges during the year which resulted in worse than expected performance,” said Mike Mikan, President and CEO of Bright Health Group. “Despite a challenging 2021, we have conviction in our strategy to continue driving alignment and integration of care delivery and financing at the local level. None of this is possible without an incredible team who deeply care about making healthcare right for consumers and we are focused on driving results off our scaled platform in 2022 and beyond.”

Key Metrics

 

 

As of December 31,

 

2021

 

2020

Consumer and Patient Metrics

 

 

 

Bright HealthCare Commercial Consumers

611,078

 

145,459

Bright HealthCare Medicare Advantage Consumers

116,621

 

61,663

NeueHealth Value-Based Patients

175,587

 

21,126

 

Three Months Ended

 

Twelve Months Ended

($ in thousands)

December 31,

 

December 31,

 

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

Financial Metrics

 

 

 

 

 

 

 

Revenue

$

962,334

 

 

$

359,778

 

 

$

4,029,389

 

 

$

1,207,320

 

Medical Cost Ratio(1)

 

134.1

%

 

 

105.4

%

 

 

101.3

%

 

 

88.7

%

Operating Cost Ratio

 

47.7

%

 

 

41.3

%

 

 

30.7

%

 

 

33.9

%

GAAP Net Loss (2)

$

(813,375

)

 

$

(163,832

)

 

$

(1,178,365

)

 

$

(248,442

)

Adjusted EBITDA (non-GAAP) (2)

$

(790,149

)

 

$

(157,724

)

 

$

(1,080,906

)

 

$

(238,912

)

(1)

 

Medical Cost Ratio for the three months ended December 31, 2021, includes a 860 basis point unfavorable impact from COVID-19 related costs and a 2,640 basis point unfavorable impact reflecting the combined impact of a cumulative reduction in Premium Revenue due to an inability to capture risk adjustment on newly added lives, as well as prior period medical costs recognized in the fourth quarter. This is compared to 2020, which included a 650 basis point unfavorable impact from COVID-19 costs and a 20 basis point unfavorable impact from non-COVID prior period developments (“PPD”). Medical Cost Ratio for the twelve months ended December 31, 2021, includes a 530 basis point unfavorable impact from COVID-19 costs, and a 90 basis point unfavorable impact from non-COVID PPD. This is compared to 2020, which included a 400 basis point unfavorable impact from COVID-19 costs, a 110 basis point favorable impact from non-COVID PPD, and a 110 basis point favorable impact due to deferred utilization.

 

 

 

(2)

 

GAAP Net Loss and Adjusted EBITDA (non-GAAP) include $102.8 million of premium deficiency reserve related to expected future losses in certain states in 2022.

See the table at the end of this release for additional information and a reconciliation of the non-GAAP measure used in the table above.

Financial Outlook

For full year 2022, Bright Health Group is providing the following guidance and commentary:

  • Bright Health Group’s total Revenue is expected to be $6.8 billion to $7.1 billion with an expected enterprise Medical Cost Ratio between 90% and 94%.
  • On a segment basis, Bright HealthCare end-of-year membership is expected to be approximately 1,000,000, while NeueHealth Revenue is expected to be approximately $2.3 billion.
  • Intercompany Revenue elimination, comprised of payments from Bright HealthCare to NeueHealth for managing patient care and for network services, is expected to be approximately $1.2 to $1.4 billion.
  • Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 and $800.0 million.

Earnings Conference Call

As previously announced, Bright Health Group will discuss the Company’s results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company’s website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K dated March 2, 2022, can be accessed on the Investor Relations page of the Company’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, Securities and Exchange filings and public conference calls and webcasts.

About Bright Health Group

Bright Health Group is the first technology-enabled, fully-aligned system of care built for healthcare’s consumer retail market. Our differentiated approach aligns care delivery with the financing of care to drive better outcomes, lower costs, and enhance the consumer experience. We have two market-facing businesses: NeueHealth and Bright HealthCare. NeueHealth provides care delivery and value-based enablement services to over 400,000 value-based patients through our owned and affiliated clinics. Bright HealthCare offers Commercial and Medicare health plan products to over one million consumers across the nation. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

Notes

A reconciliation of the projected Adjusted EBITDA, which is a forward-looking non-GAAP financial measure, to the most directly comparable GAAP financial measures, is not provided because the Company is unable to provide such reconciliation without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. These GAAP measures may include the impact of such items as interest expense, income tax expense, depreciation and amortization, share-based compensation expense; transaction costs, changes in the fair value of contingent consideration, contract termination costs; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, “non-GAAP adjustments”). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Forward-Looking Statements

Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our ability to accurately assess, code and report IFP and MA risk adjustment factor scores for our consumers; our ability to contract with care providers and arrange for the provision of quality care; our ability to accurately estimate our medical expenses, effectively manage our costs and claims liabilities or appropriately price our products and charge premiums; the impact of the ongoing COVID-19 pandemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage the growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; and the other factors set forth under the heading “Risk Factors” in Bright Health Group’s prospectus filed pursuant to Rule 424(b)(4) on June 25, 2021, and our other filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.

Bright Health Group, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

 

 

December 31,

2021

 

December 31,

2020

Assets

Current assets:

Cash and cash equivalents

$

1,061,179

 

$

488,371

 

Short-term investments

 

193,835

 

 

499,928

 

Accounts receivable, net of allowance of $4,074 and $2,602, respectively

 

113,474

 

 

60,522

 

Prepaids and other current assets

 

291,712

 

 

130,986

 

Total current assets

 

1,660,200

 

 

1,179,807

 

Other assets:

Long-term investments

 

675,192

 

 

175,176

 

Property, equipment and capitalized software, net

 

38,344

 

 

12,264

 

Goodwill

 

835,140

 

 

263,035

 

Intangible assets, net

 

343,860

 

 

152,211

 

Other non-current assets

 

45,603

 

 

28,309

 

Total other assets

 

1,938,139

 

 

630,995

 

Total assets

$

3,598,339

 

$

1,810,802

 

Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders’ Equity (Deficit)

Current liabilities:

Medical costs payable

$

817,975

 

$

249,777

 

Accounts payable

 

118,140

 

 

57,252

 

Unearned revenue

 

53,295

 

 

34,628

 

Risk adjustment payable

 

931,170

 

 

187,777

 

Short-term borrowings

 

155,000

 

 

 

 

Other current liabilities

 

207,238

 

 

35,847

 

Total current liabilities

 

2,282,818

 

 

565,281

 

Other liabilities

 

41,994

 

 

28,578

 

Total liabilities

 

2,324,812

 

 

593,859

 

Redeemable noncontrolling interests

 

128,407

 

 

39,600

 

Redeemable preferred stock, $0.0001 par value; 100,000,000 and 166,307,087 shares authorized in 2021 and 2020, respectively; — and 164,244,893 shares issued and outstanding in 2021 and 2020, respectively

 

 

 

1,681,015

 

Shareholders’ equity (deficit):

Common stock, $0.0001 par value; 3,000,000,000 and 658,993,725 shares authorized in 2021 and 2020, respectively; 628,622,872 and 137,662,698 shares issued and outstanding in 2021 and 2020, respectively

 

63

 

 

14

 

Additional paid-in capital

 

2,861,243

 

 

9,877

 

Accumulated deficit

 

(1,700,851

)

 

(515,989

)

Accumulated other comprehensive (loss) income

 

(3,335

)

 

2,426

 

Treasury stock, at cost, 2,522,148 and — shares at December 31, 2021 and 2020, respectively

 

(12,000

)

 

 

 

Total shareholders’ equity (deficit)

 

1,145,120

 

 

(503,672

)

Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)

$

3,598,339

 

$

1,810,802

 

Bright Health Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Income (Loss)

(in thousands, except share and per share data)

(Unaudited)

 

Three Months Ended December 31,

 

Twelve Months Ended December 31,

 

2021

 

 

2020

 

 

 

2021

 

 

2020

 

Revenue:

 

 

Premium revenue

$

979,764

 

$

353,203

 

 

$

3,902,714

 

$

1,180,338

 

Service revenue

 

11,099

 

 

5,170

 

 

 

42,701

 

 

18,514

 

Investment income

 

(28,529

)

 

1,405

 

 

 

83,974

 

 

8,468

 

Total revenue

 

962,334

 

 

359,778

 

 

 

4,029,389

 

 

1,207,320

 

Operating expenses:

 

 

 

 

 

Medical costs

 

1,313,531

 

 

372,186

 

 

 

3,953,674

 

 

1,047,300

 

Operating costs

 

459,297

 

 

148,684

 

 

 

1,238,387

 

 

409,334

 

Depreciation and amortization

 

9,503

 

 

2,739

 

 

 

35,484

 

 

8,289

 

Total operating expenses

 

1,782,331

 

 

523,609

 

 

 

5,227,545

 

 

1,464,923

 

Operating loss

 

(819,997

)

 

(163,831

)

 

 

(1,198,156

)

 

(257,603

)

Interest expense

 

1,674

 

 

 

 

 

7,956

 

 

 

Other income

 

 

 

 

 

(1,226

)

 

 

Loss before income taxes

 

(821,671

)

 

(163,831

)

 

 

(1,204,886

)

 

(257,603

)

Income tax (benefit) expense

 

(8,296

)

 

1

 

 

 

(26,521

)

 

(9,161

)

Net loss

 

(813,375

)

 

(163,832

)

 

 

(1,178,365

)

 

(248,442

)

Net earnings attributable to noncontrolling interests

 

(1,143

)

 

 

 

 

(6,497

)

 

 

Net loss attributable to Bright Health Group, Inc. common shareholders

$

(814,518

)

$

(163,832

)

 

$

(1,184,862

)

$

(248,442

)

Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders

$

(1.29

)

$

(1.20

)

 

$

(3.02

)

$

(1.82

)

Basic and diluted weighted-average common shares outstanding

 

629,485

 

 

136,968

 

 

 

392,243

 

 

136,193

 

Bright Health Group, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

Twelve Months Ended December 31,

 

2021

 

 

 

2020

 

Cash flows from operating activities:

Net loss

$

(1,184,862

)

$

(248,442

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

Depreciation and amortization

 

35,484

 

 

8,289

 

Share-based compensation

 

68,423

 

 

5,452

 

Deferred income taxes

 

(25,654

)

 

 

Unrealized gains on equity securities

 

(80,231

)

 

 

 

Other, net

 

20,254

 

 

2,667

 

Changes in assets and liabilities, net of acquired assets and liabilities:

Accounts receivable

 

(32,941

)

 

24,631

 

Other assets

 

(143,463

)

 

(44,061

)

Medical cost payable

 

475,461

 

 

78,591

 

Risk adjustment payable

 

742,075

 

 

100,974

 

Accounts payable and other liabilities

 

192,611

 

 

(3,962

)

Unearned revenue

 

14,902

 

 

18,623

 

Net cash provided by (used in) operating activities

 

82,059

 

 

(57,238

)

Cash flows from investing activities:

 

Purchases of investments

 

(1,017,588

)

 

(916,823

)

Proceeds from sales, paydown, and maturities of investments

 

926,901

 

 

463,887

 

Purchases of property and equipment

 

(30,414

)

 

(6,474

)

Business acquisitions, net of cash acquired

 

(431,791

)

 

(230,332

)

Net cash used in investing activities

 

(552,892

)

 

(689,742

)

Cash flows from financing activities:

Proceeds from issuance of preferred stock

 

 

 

711,200

 

Proceeds from issuance of common stock

 

11,390

 

 

1,241

 

Net proceeds from short-term borrowings

 

155,000

 

 

 

 

Payments for debt issuance costs

 

(3,391

)

 

 

 

Proceeds from IPO

 

887,328

 

 

 

 

Payments for IPO offering costs

 

(6,686

)

 

 

Net cash provided by financing activities

 

1,043,641

 

 

712,441

 

Net increase (decrease) in cash and cash equivalents

 

572,808

 

 

(34,539

)

Cash and cash equivalents – beginning of year

 

488,371

 

 

522,910

 

Cash and cash equivalents – end of year

$

1,061,179

 

$

488,371

 

Bright Health Group, Inc. and Subsidiaries

Segment Information

(in thousands)

(Unaudited)

 

Bright HealthCare

Three Months Ended

 

Twelve Months Ended

(in thousands)

December 31,

 

December 31,

Statements of income (loss) and operating data:

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

 

 

 

 

 

 

 

Bright HealthCare:

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

Commercial premium revenue

$

581,699

 

 

$

181,518

 

 

$

2,512,624

 

 

$

692,433

 

Medicare Advantage premium revenue

 

367,899

 

 

 

169,842

 

 

 

1,297,273

 

 

 

480,112

 

Investment income

 

248

 

 

 

1,405

 

 

 

3,739

 

 

 

8,468

 

Total revenue

 

949,846

 

 

 

352,765

 

 

 

3,813,636

 

 

 

1,181,013

 

Operating expenses

 

 

 

 

 

 

 

 

Medical costs

 

1,178,701

 

 

 

372,186

 

 

 

3,766,897

 

 

 

1,047,300

 

Operating costs

 

433,322

 

 

 

138,785

 

 

 

1,140,842

 

 

 

376,215

 

Depreciation and amortization

 

5,544

 

 

 

2,263

 

 

 

17,068

 

 

 

6,394

 

Total operating expenses

 

1,617,567

 

 

 

513,234

 

 

 

4,924,807

 

 

 

1,429,909

 

Operating loss

$

(667,721

)

 

$

(160,469

)

 

$

(1,111,171

)

 

$

(248,896

)

 

 

 

 

 

 

 

 

Medical Cost Ratio (MCR)

 

124.1

%

 

 

105.9

%

 

 

98.9

%

 

 

89.3

%

NeueHealth

Three Months Ended

 

Twelve Months Ended

($ in thousands)

December 31,

 

December 31,

Statements of income (loss) data:

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

 

 

 

 

 

 

 

 

NeueHealth:

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

Premium revenue

$

116,418

 

 

$

1,843

 

 

$

338,254

 

 

$

7,793

 

Service revenue

 

19,881

 

 

 

7,834

 

 

 

74,690

 

 

 

29,354

 

Investment income

 

(28,777

)

 

 

 

 

 

80,235

 

 

 

 

Total revenue

 

107,522

 

 

 

9,677

 

 

 

493,179

 

 

 

37,147

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Medical costs

 

221,142

 

 

 

 

 

 

432,318

 

 

 

 

Operating costs

 

34,697

 

 

 

12,563

 

 

 

129,430

 

 

 

43,959

 

Depreciation and amortization

 

3,959

 

 

 

476

 

 

 

18,416

 

 

 

1,895

 

Total operating expenses

 

259,798

 

 

 

13,039

 

 

 

580,164

 

 

 

45,854

 

Operating loss

$

(152,276

)

 

$

(3,362

)

 

$

(86,985

)

 

$

(8,707

)

 

 

 

 

 

 

 

 

Medical Cost Ratio (MCR)

 

190.0

%

 

 

%

 

 

127.8

%

 

 

%

Non-GAAP Financial Measures

We use the non-GAAP financial measure Adjusted EBITDA. We define Adjusted EBITDA as Net Loss excluding Interest Expense, Income Taxes, Depreciation and Amortization, adjusted for the impact of acquisition and financing-related transaction costs, share-based compensation and changes in the fair value of contingent consideration. This non-GAAP measure has been presented in this quarterly Earnings Release as a supplemental measure of financial performance that is not required by or presented in accordance with GAAP because we believe it assists management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes this measure is useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management’s discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

($ in thousands)

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

Net loss

$

(813,375

)

 

$

(163,832

)

 

$

(1,178,365

)

 

$

(248,442

)

Interest expense

 

1,674

 

 

 

 

 

 

7,956

 

 

 

 

Income tax (benefit) expense

 

(8,296

)

 

 

1

 

 

 

(26,521

)

 

 

(9,161

)

Depreciation and amortization

 

9,503

 

 

 

2,739

 

 

 

35,484

 

 

 

8,289

 

Transaction costs (a)

 

740

 

 

 

1,638

 

 

 

6,338

 

 

 

4,950

 

Share-based compensation expense (b)

 

25,189

 

 

 

1,730

 

 

 

68,423

 

 

 

5,452

 

Change in fair value of contingent consideration (c)

 

(5,584

)

 

 

 

 

 

(4,221

)

 

 

 

Contract termination costs (d)

 

 

 

 

 

 

 

10,000

 

 

 

 

Adjusted EBITDA

$

(790,149

)

 

$

(157,724

)

 

$

(1,080,906

)

 

$

(238,912

)

(a)

 

Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to business combinations and certain costs associated with our initial public offering. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business.

(b)

 

Represents non-cash compensation expense related to stock option and restricted stock award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards.

(c)

 

Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period. There was no material activity for periods prior to the first quarter of 2021.

(d)

 

Represents amount paid for early termination of an existing vendor contract.

 



Reference-www.businesswire.com

Leave a Comment